{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-192794","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.532981+00:00","generated_at":"2026-05-17T09:21:38.077743+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sarepta exchanges $700M convertible notes for $602M new 4.875% notes due 2030 plus stock and cash","bullets":["Exchanged $700M of 1.25% Convertible Notes due 2027 for $602M of 4.875% Convertible Notes due 2030, 5.85M common shares, and ~$123.3M cash.","New notes mature Sept 1, 2030; initial conversion price ~$60.00/share (191.5% premium over $20.58 close on Aug 20, 2025).","Concurrent private placement of 1,106,806 shares to J. Wood Capital at $18.07 per share.","New notes bear 4.875% cash interest, payable semiannually; callable from Sept 6, 2028 if stock price ≥ 130% of conversion price.","Holders may convert upon stock price triggers (≥130% of conversion price for 20 of 30 days) or specified corporate events."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-192794","json":"https://secwatch.observer/filing/0001193125-25-192794.json","markdown":"https://secwatch.observer/filing/0001193125-25-192794.md","text":"https://secwatch.observer/filing/0001193125-25-192794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312525192794/0001193125-25-192794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312525192794/d945054d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:21:38.077743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6688c6e36041d4f532bab75bbe7bcca8e208f25b","claim":"Sarepta Therapeutics, Inc. incurred convertible notes of $602.0 million in aggregate principal amount with U.S. Bank Trust Company, National Association at 4.875% maturing September 1, 2030.","evidence_excerpt":"party thereto agreed to exchange with the Company $700.0 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) $602.0 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”), (ii) an aggregate of 5,851,693 shares of the Company’s common stock, par","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312525192794/0001193125-25-192794-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$602.0 million in aggregate principal amount"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Rate","value":"4.875%"},{"label":"Maturity","value":"September 1, 2030"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}